

Charles H. Chevalier  
**GIBBONS P.C.**  
One Gateway Center  
Newark, New Jersey 07102-5310  
Telephone No.: (973) 596-4500  
cchevalier@gibbonslaw.com

*Of Counsel:*

David I. Berl  
Elise Baumgarten  
Kevin Hoagland-Hanson  
Rebecca A. Carter  
**WILLIAMS & CONNOLLY LLP**  
725 12th St. NW  
Washington, DC 20005  
(202) 434-5000  
dberl@wc.com  
ebaumgarten@wc.com  
khoagland-hanson@wc.com  
rebeccacarter@wc.com

*Attorneys for Plaintiffs AstraZeneca Pharmaceuticals LP,  
AstraZeneca UK Limited, Kudos Pharmaceuticals Limited,  
The University of Sheffield, and  
MSD International Business GmbH*

**UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

ASTRAZENECA PHARMACEUTICALS LP, )  
ASTRAZENECA UK LIMITED, KUDOS )  
PHARMACEUTICALS LIMITED, THE )  
UNIVERSITY OF SHEFFIELD, and MSD )  
INTERNATIONAL BUSINESS GMBH, )

*Plaintiffs,*

v.

NATCO PHARMA LIMITED and NATCO )  
PHARMA INC., )

*Defendants.*

C.A. No. 3:23-cv-00796 (RK)(TJB)

**STIPULATION AND ORDER FOR  
EXTENSION OF TIME**

Plaintiffs AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Kudos Pharmaceuticals Limited, The University of Sheffield, and MSD International Business GmbH (collectively, “Plaintiffs”), and Defendants Natco Pharma Limited and Natco Pharma, Inc. (collectively, “Defendants”), hereby submit this Joint Stipulation and Proposed Order.

WHEREAS, Plaintiffs filed their Complaint in the instant action on February 10, 2023 (ECF No. 1); and

WHEREAS, Defendants filed an Answer, Affirmative Defenses and Counterclaim on April 17, 2023 (ECF No. 12); and

WHEREAS, Plaintiffs filed an Answer to Defendants’ Counterclaims and Affirmative Defenses on May 8, 2023 (ECF No. 27); and

WHEREAS, Defendants filed a First Amended Answer, Affirmative Defenses and Counterclaim on September 5, 2023 (ECF No. 36); and

WHEREAS, the deadline for Plaintiffs to answer, move or otherwise respond to Defendants’ First Amended Answer, Affirmative Defenses and Counterclaim is October 10, 2023 (Clerk’s Text Order, Sept. 13, 2023);

IT IS HEREBY STIPULATED AND AGREED by and between the parties, subject to the approval of the Court:

1. The deadline for Plaintiffs to answer, move or otherwise respond to Defendants’ First Amended Answer, Affirmative Defenses and Counterclaim (ECF No. 36) in the above-captioned proceeding is extended through and including October 24, 2023.

Dated: October 10, 2023

s/ Charles H. Chevalier  
Charles H. Chevalier

s/ James S. Richter  
James S. Richter

**GIBBONS P.C.**

One Gateway Center  
Newark, New Jersey 07102-5310  
Telephone No.: (973) 596-4500  
cchevalier@gibbonslaw.com

*Of Counsel:*

David I. Berl  
Elise Baumgarten  
Kevin Hoagland-Hanson  
Rebecca A. Carter  
WILLIAMS & CONNOLLY LLP  
725 12th St. NW  
Washington, DC 20005  
(202) 434-5000  
dberl@wc.com  
ebaumgarten@wc.com  
khoagland-hanson@wc.com  
rebeccacarter@wc.com

*Attorneys for Plaintiffs AstraZeneca  
Pharmaceuticals LP, AstraZeneca UK Limited,  
Kudos Pharmaceuticals Limited, The  
University of Sheffield, and MSD International  
Business GmbH*

**MIDLIDGE RICHTER LLC**

645 Martinsville Road  
Basking Ridge, New Jersey 07920  
(908) 626-0622  
jrichter@midlidge-richter.com

*Of Counsel:*

Kevin Warner  
William A. Rakoczy  
Paul J. Molino  
Greg L. Goldblatt  
RAKOCZY MOLINO MAZZOCHI SIWIK  
LLP  
6 West Hubbard Street, Suite 500  
Chicago, Illinois 60654  
(312) 527-2157

*Attorneys for Defendants Natco Pharma Ltd.  
and Natco Pharma, Inc.*

It is on this 11th day of October, 2023

**SO ORDERED.**

s/Tonianne J. Bongiovanni

Hon. Tonianne J. Bongiovanni